Wayshine Biopharm, Inc.
Clinical trials sponsored by Wayshine Biopharm, Inc., explained in plain language.
-
New combo therapy targets Hard-to-Treat lung cancer
Disease control Recruiting nowThis study tests a new drug called WSD0922-FU combined with the standard drug osimertinib for people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The trial aims to see if the combination is safe and can shrink tumors. About 48 adult…
Phase: PHASE1, PHASE2 • Sponsor: Wayshine Biopharm, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New hope for lung cancer patients with stubborn mutation
Disease control Recruiting nowThis study tests an experimental oral drug called WSD0922-FU in 40 adults with advanced non-small cell lung cancer that has a specific mutation (C797S) and has stopped responding to the standard treatment osimertinib. The main goal is to see if the drug can shrink tumors. It is a…
Phase: PHASE2 • Sponsor: Wayshine Biopharm, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:42 UTC